Earlier this year, the American Association for Cancer Research (AACR) presented statistics from the National Cancer Institute (NCI) showing that the number of breast cancer cases in the US is expected to be 50% higher in 2030 than it was in 2011, increasing from a total of 283,000 cases to 441,000 cases. In 2015 alone, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the US, in addition to 60,290 new cases of noninvasive, ductal carcinoma in situ (DCIS) breast cancer, according to the most recent statistics from the American Cancer Society. Moreover, this year, 40,290 women in the US are expected to die of breast cancer.
Although the overall number of breast cancer cases is growing, the most difficult-to-treat breast cancer, estrogen-receptor (ER)-negative cancer, is declining in proportional terms. According to data from the NCI presented...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?